Frankfurt
22.11.24
08:07 Uhr
0,078 Euro
-0,008
-9,36 %
-9,36 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,083 | 0,110 | 11:59 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Ventripoint Diagnostics Ltd.: Ventripoint Announces Closing of Debt Settlement Agreements | 1 | TheNewswire | ||
| VENTRIPOINT DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| Di | Ventripoint Announces New Sales Program to Accelerate Growth in U.S. Market for AI-Powered Echocardiography Solutions | 1 | iNVEZZ.com | ||
| Di | Ventripoint Diagnostics Ltd.: Ventripoint Announces New Sales Program to Accelerate Growth in U.S. Market for AI-Powered Echocardiography Solutions | 1 | TheNewswire | ||
| 16.11. | Ventripoint Diagnostics Ltd (2): Ventripoint 2,845,771-share private placement | 2 | Stockwatch | ||
| 14.11. | Ventripoint Diagnostics Ltd (2): Ventripoint closes final tranche of private placement | 1 | Stockwatch | ||
| 14.11. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Closing of Second and Final Tranche of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption | 1 | TheNewswire | ||
| 06.11. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Amended Non-Brokered Convertible Debenture Private Placement and Shares for Debt Transaction | 2 | TheNewswire | ||
| 24.10. | Ventripoint Diagnostics Ltd (2): Ventripoint receives CE Mark certification for VMS+4.0 | 2 | Stockwatch | ||
| 24.10. | Ventripoint to debut new AI heart-scanning tech in Europe | 3 | The Market Herald Canada | ||
| 24.10. | Ventripoint Diagnostics Ltd.: Ventripoint Receives EU CE Mark for Next Generation, AI-powered Heart-scanning Technology | 1 | TheNewswire | ||
| 24.10. | Ventripoint Receives EU CE Mark for Next Generation, AI-powered Heart-scanning Technology | 1 | iNVEZZ.com | ||
| 18.10. | Ventripoint Diagnostics Ltd (2): Ventripoint closes $458,587 first financing tranche | 1 | Stockwatch | ||
| 18.10. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Closing of First Tranche of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption | 1 | TheNewswire | ||
| 15.10. | Ventripoint Diagnostics Ltd (2): Ventripoint extends placements, increases LIFE offering | 3 | Stockwatch | ||
| 15.10. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Extension of Private Placement Offerings and Upsize of Non-Brokered Private Placement Pursuant to Listed Issuer Financing Exemption | 3 | TheNewswire | ||
| 11.10. | Ventripoint Diagnostics Ltd (2): Ventripoint submits VMS+4.0 for EU MDR approval | 1 | Stockwatch | ||
| 11.10. | Stocks in Play: Ventripoint Diagnostics Ltd. | 1 | Baystreet.ca | ||
| 11.10. | Ventripoint Diagnostics Ltd.: Ventripoint's Next Generation, AI-powered Heart-Scanning Technology Submitted for EU Medical Device Regulation Certification | 1 | TheNewswire | ||
| 08.10. | Ventripoint Diagnostics Ltd (2): Ventripoint Diagnostics completes three quality audits | 1 | Stockwatch | ||
| 08.10. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Successful Completion of Key Quality Audits | 1 | TheNewswire |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS | 1,164 | -0,34 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium | SEATTLE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical stage biopharmaceutical company developing innovative medicines in areas... ► Artikel lesen | |
| TANDEM DIABETES | 30,080 | +1,69 % | Kim Blickenstaff verkauft Tandem Diabetes-Aktien im Wert von 1,24 Millionen US-Dollar | ||
| VERU | 0,586 | -9,65 % | Veru Inc.: Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results | --Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected... ► Artikel lesen | |
| MOLINA HEALTHCARE | 277,20 | -0,68 % | Peering Into Molina Healthcare's Recent Short Interest | ||
| CLOVER HEALTH INVESTMENTS | 3,270 | +1,18 % | Clover Health Investments, Corp.: Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer | FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D.... ► Artikel lesen | |
| COGNETIVITY NEUROSCIENCES | 0,015 | -100,00 % | XFRA 1UB: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCOGNETIVITY NEUROC.... ► Artikel lesen | |
| SEMLER SCIENTIFIC | 62,00 | +0,81 % | Semler Scientific stock hits 52-week high at $58.94 | ||
| TEMPUR SEALY | 51,00 | +2,00 % | Dividendenbekanntmachungen (21.11.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 3I INFRASTRUCTURE PLC JE00BF5FX167 0,0632 GBP 0,0759 EUR ALLIENT INC US0193301092 0,03 USD 0,0284 EUR ALUMINUM CORPORATION OF CHINA... ► Artikel lesen | |
| SHL TELEMEDICINE | 2,700 | 0,00 % | SHL Telemedicine Ltd.: SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine | David Arnon held senior leadership and CEO roles within the healthcare insurance industry at Harel Insurance and Clal Insurance, two of the largest insurance groups in Israel
SHL Telemedicine Ltd.... ► Artikel lesen | |
| SINTX TECHNOLOGIES | 5,000 | +16,28 % | SINTX Technologies, Inc.: SINTX Technologies and NED Medical Partner to Advance Cutting-Edge Ceramic Microsphere Medical Devices for Cancer Treatment | ||
| SMILEDIRECTCLUB | 0,004 | 0,00 % | Align to pay $27.5M to SmileDirectClub clients as antitrust lawsuit nears settlement | ||
| NEURONETICS | 0,800 | +10,65 % | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve... ► Artikel lesen | |
| FRESENIUS | 33,310 | +1,59 % | Fresenius SE Aktie: Erfolgreiche Initiativen stärken Marktstellung! | ||
| SIEMENS HEALTHINEERS | 49,800 | +1,36 % | Siemens Healthineers Aktie: Fortschrittliches Denken zahlt sich aus! | Die Siemens Healthineers-Aktie verzeichnete am Handelstag eine erfreuliche Entwicklung mit einem Kursgewinn von 1,5 Prozent auf 49,86 Euro im XETRA-Handel. Im Tagesverlauf erreichte das Papier sein... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 42,250 | +1,95 % | GOLDMAN SACHS stuft FMC FRESENIUS MEDICAL CARE AG & CO KGAA auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für FMC von 49 auf 52 Euro angehoben und die Einstufung auf "Buy" belassen. Die Ergebnisse des dritten Quartals seien... ► Artikel lesen |
Das Unternehmen VENTRIPOINT DIAGNOSTICS LTD kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,078 Euro und damit -9,36 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VENTRIPOINT DIAGNOSTICS LTD finden Sie auf Wallstreet Online.
